# Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer

> **NCT02933944** · PHASE1 · TERMINATED · sponsor: **Targovax ASA** · enrollment: 6 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **BIOLOGICAL:** TG02-treatment
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02933944
- **Lead sponsor:** Targovax ASA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2019-02
- **Final completion:** 2019-09
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Changing priorities
- **Last updated:** 2022-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02933944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02933944, "Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02933944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*